ArticleJAMA network open2022
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Maternal Area of Residence and Outcomes for Mother-Infant Dyads with Perinatal Opioid Exposure.American journal of perinatology · 2026Trial
- Patient Travel Experiences for Methadone Dosing Visits.JAMA network open · 2026Article
- Differential associations between social determinants of health and the initiation of medications for opioid use disorder across care settings.npj health systems · 2026Article
- Characterizing the Geography of Drug Use Networks and Behaviors Among People Who Inject Drugs in the Baltimore Metropolitan Region.AIDS and behavior · 2026Article
- Medications for opioid use disorder, recovery supports, and overdose risk -- a database linkage study of a rural cohort of people who inject drugs and use opioids.BMC public health · 2026Article
- "It's so much easier for them to just come to us": a qualitative study examining the implementation of mobile methadone treatment serving a residential SUD treatment program.Addiction science & clinical practice · 2026Article
- Substance use treatment and overdose patterns in high and low social vulnerability counties: a trends analysis in New Jersey from 2014-2022.Addictive behaviors reports · 2026Article
- Treating Opioid Use Disorder With Methadone in Pharmacies.JAMA network open · 2026Article
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025Review
- Multilevel Factors Associated With Hospitalizations in the First-Year Postpartum Among Persons With Opioid Use Disorder.Substance use & addiction journal · 2025Article
- A participatory photovoice investigation of community assets, barriers, and opportunities to curb the opioid epidemic.Journal of substance use and addiction treatment · 2025Article
- The impact of buprenorphine prescriber data on geospatial access to treatment in HEALing Communities Study communities, 2022.Journal of substance use and addiction treatment · 2025Article
- "I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.Journal of substance use and addiction treatment · 2025Article
- Community-level factors influencing the duration of buprenorphine treatment in individuals with opioid use disorder: a cohort study using US longitudinal claims data.BMJ public health · 2025Article
- Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough.Substance abuse treatment, prevention, and policy · 2024Observational
- Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.JAMA network open · 2024Article
- Delivering MOUD to the Underserved: How Can Pharmacies Really Help?Journal of studies on alcohol and drugs · 2024Article
- Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios.PLoS computational biology · 2024Article
- Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019-2022.American journal of preventive medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Importance: Given that COVID-19 and recent natural disasters exacerbated the shortage of medication for opioid use disorder (MOUD) services and were associated with increased opioid overdose mortality, it is important to examine how a community's ability to respond to natural disasters and infectious disease outbreaks is associated with MOUD access. Objective: To examine the association of community vulnerability to disasters and pandemics with geographic access to each of the 3 MOUDs and whether this association differs by urban, suburban, or rural classification. Design, Setting, and Participants: This cross-sectional study of zip code tabulation areas (ZCTAs) in the continental United States excluding Washington, DC, conducted a geospatial analysis of 2020 treatment location data. Exposures: Social vulnerability index (US Centers for Disease Control and Prevention measure of vulnerability to disasters or pandemics). Main Outcomes and Measures: Drive time in minutes from the population-weighted center of the ZCTA to the ZCTA of the nearest treatment location for each treatment type (buprenorphine, methadone, and extended-release naltrexone). Results: Among 32 604 ZCTAs within the continental US, 170 within Washington, DC, and 20 without an urban-rural classification were excluded, resulting in a final sample of 32 434 ZCTAs. Greater social vulnerability was correlated with longer drive times for methadone (correlation, 0.10; 95% CI, 0.09 to 0.11), but it was not correlated with access to other MOUDs. Among rural ZCTAs, increasing social vulnerability was correlated with shorter drive times to buprenorphine (correlation, -0.10; 95% CI, -0.12 to -0.08) but vulnerability was not correlated with other measures of access. Among suburban ZCTAs, greater vulnerability was correlated with both longer drive times to methadone (correlation, 0.22; 95% CI, 0.20 to 0.24) and extended-release naltrexone (correlation, 0.15; 95% CI, 0.13 to 0.17). Conclusions and Relevance: In this study, communities with greater vulnerability did not have greater geographic access to MOUD, and the mismatch between vulnerability and medication access was greatest in suburban communities. Rural communities had poor geographic access regardless of vulnerability status. Future disaster preparedness planning should match the location of services to communities with greater vulnerability to prevent inequities in overdose deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.